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Contraception and unplanned pregnancies 
Helena Hognert 
Department of Obstetrics and Gynecology, Institute of Clinical Sciences 
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 
Abstract 
Aims: The overall aim of this thesis was to describe the relationship between contraceptive 
use, abortion, birth and fertility rates among women in different age groups in Sweden and the 
other Nordic countries.  
Material and methods: Data on contraception, fertility, birth, and abortion from 1975-2015 
was collected from national databases in the five Nordic countries Denmark, Finland, Iceland, 
Norway and Sweden (Paper I-III). In Paper IV data on reproductive health and socio-
economic status (SES) was collected mainly from questionnaires sent to four cohorts of 19-
year-old women resident in Gothenburg between 1981 and 2011. Paper V was a multicentre 
randomised controlled equivalence study where the impact of immediate versus delayed 
insertion of an etonogestrel releasing contraceptive implant on complete abortion rates after a 
medical abortion was evaluated.  
Results: The user rates of hormonal contraceptives and a copper intrauterine device among 
all women aged 15-49 years in the Nordic countries varied between 31% and 44%. The 
highest use was in Denmark and the lowest in Iceland. Combined hormonal contraceptives 
(CHC) were the most common methods. A small increase of long-acting reversible 
contraception (LARC) was seen. The user rates of hormonal contraceptives among 18-19 
years old teenagers varied between 54% and 63%. CHC were the most common methods, but 
LARC increased more than in the group of women aged 15-49 years. The overall abortion 
rates in the Nordic countries fell during the study period. The average fertility and birth rates 
in the Nordic countries remained stable. Teenage birth and abortion rates declined 
continuously 1975-2015. There was no clear correlation between higher overall hormonal 
contraception prevalence and lower abortion rate. Instead other factors have to be considered, 
such as differences in the proportions of different types of hormonal contraceptives and 
prevalence in specific age groups. Lower contraceptive use in low SES areas compared to 
middle and high SES areas was detected in the most recent assessment of 19 years-old 
women. Equivalence was established for the two insertion modes of a contraceptive implant.  
Conclusions: On a global scale the Nordic countries have a high prevalence of contraceptive 
use, low abortions rates and a stable fertility rate, except for teenagers where a steady decline 
in both births and abortions was found. An association between low SES and low 
contraceptive use among 19-year-olds in the most recent assessment was found which might 
imply widening inequalities. A contraceptive implant can be inserted on the same day as 
administration of mifepristone for early medical abortion without hampering the abortion.  It 
has the potential to increase the number of women who can receive the most effective 
methods of contraception at the time of abortion.  
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Sammanfattning på svenska 
Tillgång till preventivmedel och abort är en viktig del i sexuell och reproduktiv 
hälsa som ger möjlighet att själv bestämma när och hur många barn man vill ha. 
Hög preventivmedelsanvändning i ett land går ofta hand i hand med lågt antal 
oplanerade graviditeter och aborter, men alla tre parametrarna kan också 
påverkas av många andra faktorer. Det övergripande syftet med avhandlingen 
var att beskriva och analysera förhållandet mellan preventivmedelsanvändning, 
aborter, födslar och fertilitetsnivå hos kvinnor i olika åldersgrupper i Sverige 
och dom andra nordiska länderna.  
I studie I-II användes data, som samlats in från nationella databaser i alla dom 
nordiska länderna, gällande uttagna recept på preventivmedel, sålda 
kopparspiraler, antal aborter, födslar och fertilitetsgrad för samtliga kvinnor i 
åldern 15-49 år. I studie III användes data, som samlats in på samma vis, 
gällande uttagna recept på preventivmedel, antal aborter och födslar för 
tonåringar, 13-19 år. Studie IV baserades i huvudsak på svar från enkäter 
gällande reproduktiv hälsa, som skickats till fyra grupper med slumpmässigt 
utvalda 19-åriga kvinnor i Göteborgsområdet med 10 års intervall under åren 
1981-2011. Studie V var en randomiserad kontrollerad ekvivalensstudie där 
insättning av en p-stav i direkt anslutning till att en abort startades eller vid ett 
återbesök jämfördes avseende eventuella effekter på aborten. 
I studie I-II fann man att andelen kvinnor i åldern 15-49 år i dom nordiska 
länderna som använde ett hormonellt preventivmedel eller kopparspiral 
varierade mellan 31 och 44% åren 2008-2013. Danmark hade högst användartal 
o Island lägst. Kombinerade metoder (p-piller, p-ring, p-plåster) var dom 
vanligaste metoderna, men en liten ökning av långverkande reversibla metoder 
(p-stav och spiraler) kunde ses.  Andelen födslar och fertilitetsgrad låg stabilt 
under åren 1975-2013 för alla länder utom Island där man såg en nedgång. 
Andelen aborter minskade i Danmark och Finland, låg stabilt i Sverige och 
Norge samt ökade på Island under åren 1975-2013. 
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I studie III såg man att andelen 18-19-åringar i Danmark, Norge och Sverige 
som använde hormonella preventivmedel varierade mellan 54% och 63% under 
åren 2008-2015. Kombinerade metoder var vanligast, men man fann en större 
ökning av långverkande reversibla metoder jämfört med hela gruppen kvinnor i 
åldern 15-49 år i studie I-II. Både abort- och födslofrekvensen gick kontinuerligt 
ner bland tonåringarna i dom nordiska länderna under åren 1975-2015.  
Det fanns ingen tydlig korrelation mellan högre preventivmedelstal och lägre 
aborttal i dom nordiska länderna. Andra faktorer som skulle kunna påverka 
dessa parametrar noterades. Olika typer av hormonella preventivmedel har olika 
hög säkerhet och följsamhet och fördelningen av olika hormonella 
preventivmedelsmetoder skilde sig något åt mellan länderna. Även andelen 
preventivmedelsanvändare skilde sig åt i olika åldersgrupper.  
I studie IV noterades år 2011 en lägre preventivmedelsanvändning bland 19-
åringar i Göteborg i områden med lägst socioekonomisk status jämfört med 
övriga områden.  Detta kunde inte ses 1981, 1991 och 2001.  
Studie V visade att det är lika säkert, avseende om en medicinsk abort blir 
genomförd utan komplikationer, att sätta in en p-stav i direkt anslutning till 
besöket på abortmottagningen som ifall den sätts in vid ett återbesök efter 2-4 
veckor. I studien såg man också att en större andel kvinnor i den tidiga gruppen 
fick sin p-stav insatt än i den sena gruppen, en större nöjdhet med att få ett 
preventivmedel insatt direkt istället för vid ytterligare ett besök samt en lägre 
andel graviditeter inom ett halvår efter aborten. 
Sammanfattningsvis har dom nordiska länderna, jämfört med resten av världen, 
en hög preventivmedelsanvändning, låga aborttal och stabil fertilitetsgrad 
förutom hos tonåringar där både andelen aborter o födslar minskar. En 
nytillkommen association mellan låg socioekonomisk status och låg 
preventivmedelsanvändning hos 19-åringar noterades. Insättning av en p-stav i 
direkt anslutning till en medicinsk abort är en säker metod och ökar möjligheten 
för kvinnor att få ett preventivmedel med mycket hög säkerhet. 	
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Introduction 
Easy access to contraception and abortion is an essential part of sexual and 
reproductive health rights (SRHR) since it enables individuals and couples to 
decide when and how many children they want to have. Access to family 
planning methods is also a cornerstone in the fight to reduce poverty, maternal 
and infant mortality and to increase educational level, especially for girls and 
women. The United Nations (UN) has taken several big steps to increase access 
to family planning services. The first was the Programme of Action at the 
International Conference on Population and Development in 1994 in Cairo with 
the goal to provide access to a full range of safe and reliable family-planning 
methods by 2015.[1] Although improvements have been seen the mission was 
not accomplished and therefore another important step was taken when the UN 
General Assembly adopted the Sustainable Development Goals (SDG) in 2015 
where Goal nr 3 includes: 
“By 2030, ensure universal access to sexual and reproductive health-care 
services, including for family planning, information and education, and the 
integration of reproductive health into national strategies and programmes.” 
Family planning indicators include “Contraceptive prevalence rate” and “Unmet 
need for family planning”.[2] 
 
Contraception from a global and regional perspective 
Global, regional and country-specific levels of contraceptive prevalence rates 
are presented regularly by the Department of Economic and Social Affairs, 
Population Division at the UN.[3] Until recently the reports from the UN has 
consisted of contraceptive prevalence among women who are married or in-
union since this is how the majority of countries in the world have presented 
their data. In the future the aim is to include all women of reproductive age 
irrespective of their marital or in-union-status.[4] This is a welcome change 
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since individuals who are not currently in union might also have a need for 
contraceptives. It will also make comparisons between Europe and other parts of 
the world easier to perform since European surveys of contraceptive prevalence 
more often include all women of reproductive age. This is also the case in the 
studies included in this thesis. 
In the UN report from 2015 contraceptive prevalence among women married or 
in-union in the world was 64% with the lowest prevalence in Chad (6%) and the 
highest in China (83%). 57% of the contraceptives used were considered 
modern methods and included IUDs, sterilisation, condoms, diaphragms, all 
kinds of contraceptive pills, injectables, rings and patches, while the rest 
consisted of traditional methods such as coitus interruptus/withdrawal and safe 
periods. Regionally, Middle and Western Africa had the lowest prevalence (23% 
and 17% respectively) and Eastern Asia the highest (81%) (Figure 1).  
 
 
 
Figure 1. Percentage of women using any method of contraception among those 
aged 15 to 49 who are married or in-union 2015. Source: Trends in 
Contraceptive Use Worldwide 2015. United Nations, Department of Economic 
and Social Affairs, Population Division (2015). 
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Contraceptive use has increased over time worldwide until approximately the 
year 2000 when the rate started to stabilise in all parts of the world except for 
Africa where it is still increasing, although from a lower level (Figure 2). 
 
Figure 2. Contraceptive prevalence (any method) among married or in-union 
women, by regions, from 1970 to 2030. Source: World Family Planning 2017 – 
Highlights. United Nations, Department of Economic and Social Affairs, 
Population Division (2017).  
 
Method-specific contraceptive prevalence varies to a great extent across the 
world. In 2015 female sterilisation was the most common method in Asia (24%) 
and Latin America and the Caribbean (26%) among married or in-union women 
while the pill was the most common method in Europe (22%) and Oceania 
(22%). IUDs had their highest prevalence in Asia (17%, especially in China 
where it was 38%) and the male condom in Europe (17%) (Figure 3).[5] 
European surveys confirm the results of the UN publications indicating a high 
prevalence of contraceptive pill use in Europe. However within Europe there is a 
great variation. In a cross-sectional study from 2008[6], which included women 
15-49 years of age (irrespective of marital status) from 14 countries in different 
parts of Europe, 49% of the French and 38% of the German, but only 16% of the 
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Figure 3. Contraceptive prevalence among married or in-union women aged 15 
to 49 by method and region, 2015. Source: Trends in Contraceptive Use 
Worldwide 2015. United Nations, Department of Economic and Social Affairs, 
Population Division (2015). 
 
Baltic women relied on contraceptive pills. Condom use was more common in 
Southern Europe, with the highest prevalence in Italy (39%). In Scandinavia, 
which included Denmark, Norway and Sweden, 29% of the women relied on 
contraceptive pills, 15% on any kind of IUD/IUS and 11% on the male 
condom.[6] In another large cross-sectional European survey from 2011 women 
18-49 years of age from France, Germany, Rumania, Sweden and the UK were 
included. The results confirm the findings from the study from 2008, but with 
slightly higher user rates, which might reflect the different age group; 18-49 
instead of 15-49. The pill was used by 54% in Germany, 51% in France, 35% in 
Sweden, 24% in the UK and 22% in Romania. Male condom was the second 
most common method in all countries.[7] 
Neither the UN reports nor the European surveys discriminate between different 
kinds of oral contraceptive pills. Also copper-intrauterine devices (Cu-IUD) and 
levonorgestrel-releasing intrauterine systems (LNG-IUS) are included in the 
same group in the above-mentioned reports except for the study by Cibula et 
al.[6] 
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Although the prevalence of contraceptives is high in the Nordic countries 
including Denmark, Finland, Iceland, Norway and Sweden there is still a small 
proportion of unmet need for contraceptives. According to the UN report the 
unmet need varied between 6 and 10% in the Nordic countries among married or 
in-union women. This was confirmed by a cross-sectional study in Sweden in 
2015 where women 16-49 years of age were included and reported an unmet 
need of 9%.[8] 
 
Contraceptive methods 
Before the introduction of the pill in 1960[9] women and men had to rely on 
different kinds of condoms, cervical caps, IUDs and fertility awareness methods 
with highly varying efficacy and safety as birth control. The development of 
vulcanisation of rubber by Hancock and Goodyear led not only to the production 
of tyres, but also of cheap and functional rubber condoms in the 1850s which 
replaced the expensive and less efficient condoms made of e.g. animal intestines 
and silk.[10] One of the first intrauterine devices was introduced by Gräfenberg 
in Europe in the 1920s but the IUDs did not start to gain acceptance until the 
1950s.[11] 
After the introduction of the first combined oral contraceptive pill in the USA a 
number of other hormonal methods have been developed relying on the same 
pharmacologic mechanism as the first pill. But at the same time as the first pill 
was introduced also a new view on sexuality and contraception evolved, which 
made way for further development and refinement of other already existing 
contraceptive methods such as the IUD and condoms. 
The efficacy of a contraceptive method is measured according to the Pearl Index 
(PI), which is defined as the number of women who get pregnant during the first 
year of use among 100 women using a given method. The lower the PI the more 
effective the method. Today the following contraceptive methods are available: 
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• Combined hormonal contraceptives (CHC): Combined oral contraception 
(COC), vaginal rings, patches and injections  
• Progestogen-only methods: Progestogen-only pill (POP), implants, 
injections and LNG-IUSs  
• Cu-IUDs  
• Emergency contraception  
• Barrier methods –condoms, diaphragms 
• Male and female surgical sterilisation  
• Fertility awareness methods  
• Lactational amenorrhea method (LAM) 
• Withdrawal/coitus interruptus 
CHC 
This is the method of the first original ”pill”. CHC consists of both an estrogen 
and a progestogen component where the progestogen has the main contraceptive 
effect, by preventing fertilisation, mainly by inhibiting ovulation and thickening 
cervical mucous. 
Estrogen mainly contributes to stabilising the bleeding pattern.[12] The most 
common form is the COC, while patches and vaginal rings are less used. In 
some parts of the world, but not the Nordic countries, also a combined injection 
is available.[13] The CHC has many health advantages such as decreased 
dysmenorrhea and menorrhagia and lower risk of ovarian, endometrial and 
colon cancer apart from its contraceptive effect. The main disadvantage of CHC 
is the risk of venous tromboembolism (VTE).[12] In Europe COC is one of the 
most common contraceptives used.[5] 
 
Progestogen-only methods 
In contrast to CHC progestogen-only methods contain only a progestogen, 
which is still the main contraceptive agent. The bleeding pattern is more 
unpredictable compared to CHC, but the risk of VTE is considered to be 
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eliminated with the majority of the progestogen-only methods. The LNG-IUS is 
a safe method with a fairly predictable bleeding pattern, while the POP is more 
unpredictable. The subcutaneous implant is considered the safest contraceptive 
method available, but can also cause irregular bleeding. The injection offers a 
high rate of amenorrhea but can cause osteoporosis when used for more than 
two years.[14] 
 
Cu-IUD 
The Cu-IUD consists of a plastic frame with copper attached to it and is inserted 
into the uterus where its main contraceptive action is interference with the 
sperms ability to move in the uterine cavity and hence not reach the egg. Cu-
IUD offers a hormone-free alternative to women with conditions where 
hormones are contraindicated. The disadvantages is the risk for dysmenorrhea 
and menorrhagia.[12] 
 
Emergency contraception 
There are three types of emergency contraception –Cu-IUD, levonorgestrel 
(LNG) pills and ullipristal acetate (UPA) pills. LNG and UPA primarily prevent 
or postpone ovulation. LNG can be administered up to 72h and UPA until 120h 
after unprotected intercourse. In a randomised trial LNG prevented 69% and 
UPA 85% of the pregnancies that could be expected and therefore UPA is 
recommended as the first choice of oral emergency contraception.[15] 
IUDs can be inserted up to five days after intercourse and prevent about 99% of 
pregnancies after an episode of unprotected sex. This makes the IUD the most 
effective form of emergency contraceptive.[16] 
 
Barrier methods 
These methods work by physically preventing sperm from entering 
the uterus. They include male condoms, female condoms, cervical caps, 
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diaphragms and contraceptive sponges impregnated with spermicide. Since they 
are highly user-dependent the PI varies extensively between perfect and typical 
use. Condoms are the only method that also protect against Sexual Transmitted 
Infections (STI).[12] 
 
Male and female surgical sterilisation  
Surgical sterilisation is available in the form of tubal ligation for women 
and vasectomy for men. Female sterilisation has been one of the most common 
methods in parts of the world but has now started to give way for IUDs instead. 
With tubal ligation, complications occur in 1 to 2 percent of procedures with 
serious complications usually due to the anesthesia. The methods are highly 
efficient with a PI of 0,5 for female sterilisation and 0,15 for male sterilisation 
and should be considered irreversible.[17 18] 
 
Fertility awareness methods  
The aim of fertility awareness methods is to determine the most fertile days of 
the menstrual cycle and indicate what days to avoid unprotected sexual 
intercourse. This could include monitoring basal body temperature, cervical 
secretion or simply the day of the cycle. The latest contribution in this group of 
methods is applications for mobile phones, which help to predict safe and unsafe 
periods. The methods are highly user-dependent and therefore the PI varies 
extensively between perfect and typical use. [14] 
 
Lactational amenorrhea method (LAM) 
The LAM is used correctly if the woman has post-partum amenorrhea, if 
breastfeeding is the infant´s only source of food and no more than 6 months has 
passed since childbirth. If all the three criteria of LAM are met the failure rate is 
between 0.45 and 2.45% according to a Cochrane review.[19] 
 
  21 
Withdrawal/coitus interruptus 
Withdrawal means ending intercourse before ejaculation. The main risk of the 
withdrawal method is that the man may not perform the manouver correctly or 
in time. Since it is very user-dependent there is a great difference between 
perfect and typical use. In 2015 the prevalence in the world was 3% among 
married or in-union women, but in Southeast Europe and Western Asia a larger 
amount of couples rely on this method.[14] 
 
Efficacy of different contraceptive methods  
The efficacy of different types of contraception varies extensively. Pregnancy 
rates during perfect use shows how effective a method can be when the 
directions for use are followed completely correct. Pregnancy rates during 
typical use shows how effective a method is during actual use including 
inconsistent or incorrect use. Many methods are considered very safe when used 
perfectly, but the more user-dependent a method is the bigger the risk for 
inconsistent or incorrect use. Trussell et al reviewed the evidence of perfect and 
typical use of the contraceptive methods available (Table 1).[18] In the table it is 
notable that for the almost non-user-dependent methods, consisting of 
sterilisation and the long-acting reversible contraceptives (LARC) LNG-IUS, 
Cu-IUD and implants, perfect and typical use are almost identical. The other 
methods, which have to be taken or used at a certain time, show a greater 
variance between typical and perfect use, especially the non-hormonal methods. 
Studies among women seeking abortion have identified inconsistent or incorrect 
use of user-dependent and short-acting contraceptives and/or recent change to 
another method as possible causes for an unintended pregnancy.[20 21] In the 
CHOICE study it was shown that LARC decreased the risk of repeated 
abortions and teen pregnancies to a larger extent compared to short-acting 
methods.[22] 
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Table 1. Pear index (PI) during perfect and typical use. Source: Trussell J. 
Contraceptive failure in the United States. Contraception 2011;83(5):397-404 
and Antikonception – behandlingsrekommendation. Information från 
Läkemedelsverket 2014;25(2):14–28. 
 
Percentage of women experiencing an unintended pregnancy 
within the first year of use (PI) 
 Method Perfect use Typical use 
No method	 85	 85	
Male sterilisation	 0,10	 0,15	
Female sterilisation	 0,5	 0,5	
LNG-IUS (Mirena)	 0,2	 0,2	
Cu-IUD (≥ 300 mm2)	 0,6	 0,8	
COC and POP	 0,3	 9	
Patch	 0,3	 9	
Vaginal ring	 0,3	 9	
Injection (Depo-Provera)	 0,2	 6	
Implant (Implanon)	 0,05	 0,05	
Diaphragm with spermicides	 6	 12	
Spermicides	 18	 28	
Male condom	 2	 18	
Female condom	 5	 21	
Withdrawal	 4	 22	
Fertility awareness methods	 0,4–5	 24	
 
 
Induced abortion from a global and regional perspective 
Sedgh et al. have collected and evaluated global data on abortion rates on a 
regular basis and the latest report published in 2016 covers abortion rates from 
1990-2014.[23] Abortion rates on global, regional or country level are often 
defined as number of abortions/1000 women 15-44 years of age in one year. 
Marital status or other age groups can be included in the definition of sub 
groups. From 1990-1994 to 2010-2014 the overall global abortion rate did not 
change significantly (40 to 35/1000 women) but in the developed countries it 
fell from 46 to 27/1000 women compared to developing countries were there 
was no significant difference (39 to 37/1000 women). On a regional level the 
Caribbean and South America displayed the highest rates (59 and 48/1000 
women respectively) while the lowest rates were in Northern America at 17 and 
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Western and Northern Europe at 16 and 18/1000 women respectively. Eastern 
Europe showed the largest decline from 88 to 42/1000 women (Figure 4).[23]  
Abortion rates in the Nordic countries have been monitored closely since the 
liberalisation of the abortion laws in the 1970s. On a global scale the abortion 
rate for the Nordic countries is low at around 15/1000 women 15-44 years of 
age in 2015 and the abortion rate in the region has fallen from 1975 and 
onwards.[24] 
   
 
Figure 4. Global and regional incidence rate estimates (per 1000 women aged 
15-44 years), 1990-94 to 2010-14. Source: Abortion incidence between 1990 
and 2014:global, regional and subregional levels and trends. Sedgh, G et al. 
Lancet 2016 July; 388(10041) 
 
According to a study by WHO and the Guttmacher Institute[25] only 55% of all 
abortions were safe in 2010-2014, which means that 25 million abortions a year 
were performed in an unsafe manner.  An abortion is classified as safe if it is 
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performed by a trained health worker using a method recommended by the 
WHO. 14% of all abortions 2010-2014 were classified as “least safe”, indicating 
they were performed by an untrained person using a non-recommended and 
often dangerous method. 31% were classified as “less safe” abortions and were 
either performed by trained personnel but with out-dated methods or without a 
trained health worker but with a recommended method. The highest mortality 
and morbidity levels were seen where least safe abortions were performed, as 
was the case in Eastern, Middle and Western Africa. In Latin America 60% of 
all abortions were classified as less safe, but the fatality case rates were much 
lower than in areas with least safe abortions.[25] This probably reflects the 
increasing self-administration of medical abortion with recommended drugs and 
doses despite restrictive abortion laws, but also health care systems that are able 
to manage complications.[26]  
The overall abortion rate is higher in countries with very restrictive abortion 
laws than countries with liberal laws, which often reflects poor family planning 
resources, including access to contraceptives, in general.[25] 
 
The relationship between contraception and abortion 
prevalence  
 
Increasing contraception prevalence often leads to decreasing abortion rates, but 
is not observed at every point of time. During the 20th century and especially 
after the 1950s many countries have gone through a period of fertility transition 
with dramatic falls in Fertility Rates (FR) (Figure 5). 
The desire for a lower FR or fewer children has been driven by women’s 
empowerment and the increasing well-being and status of children. This has 
been achieved due to e.g. better health care services,, demands for education of 
women, technological and economic changes and changing norms. Family 
planning facilities have been a means to reach the desired FR. [27] Even in 
countries where contraceptive use has increased the increase has not always 
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been enough to achieve the desired FR and then abortion rates have increased 
simultaneously. When the country has  reached  the  desired  FR,  abortion  rates 
  
Figure 5. Total fertility rates 1950-2015.  
Source: OurWorldInData.org/fertility-rate. UN Population Division (2017 
revision) 
 
have often started to fall while the contraceptive use remains stable or continues 
to increase. The abortions that still occur then are mainly due to contraceptive 
failure and to a lesser extent due to an unmet need for contraception.[28-30] In 
other countries an increase in contraception prevalence has been accompanied 
by an immediate fall in the abortion rate. This has been the case in e.g. the 
former republics of the Soviet Union, where abortion was available but modern 
contraceptive methods were almost entirely absent during the Soviet era. 
Following the dissolution of the Soviet Union in 1991 there has been an inflow 
of contraceptives and the need for abortion has declined.[30] 
When reviewing the latest updates of contraceptive prevalence and abortion 
rates in different regions of the world there are some discrepancies. For instance 
Latin America and Caribbean (LAC) has a high rate of modern contraceptive 
methods and a high rate of abortions, even though the region has reached a low 
FR.[27] According to Sedgh et al. 29% of all abortions are performed by women 
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not married or in-union[23], but when contraception prevalence is described 
only women who are married or in-union are included. Hence the contraception 
prevalence might be much lower among sexually active women who are not 
married or in union. Also LAC has a high prevalence of modern contraceptives, 
but the greatest proportion consists of female sterilisation. This is a very safe 
method usually used when a woman has decided not to have any more children, 
but before that she might have many years of an unmet need for contraception 
and being at a high risk of unintended pregnancies and abortions. 
 
Abortion methods 
There are written testimonies about abortions that took place e.g. among the 
ancient Greeks, in the Roman empire and later on, but it is very difficult to 
estimate any rates. Many of the older abortion methods have proved to be either 
useless or dangerous to the woman and it was not until the 20th century safe 
methods started to evolve. Medical abortions were performed with intra-
amniotic injections of hypertonic saline, hyperosmololar urea or extraamniotic 
injection of the antiseptic ethacridine lactate. The latter was a fairly safe method, 
but with a long induction-abortion interval.[31] The introduction of 
prostaglandin analogues in the 70s and the progesterone inhibitor mifepristone 
in the 80s for medical abortion changed abortion practice dramatically and now 
provides a safe regimen also in areas where healthcare services are scarce.[32-
35] 
Medical abortion 
The most common medical procedure is the administration of the progesterone 
inhibitor mifepristone followed by the prostaglandin analogue misoprostol 24-
48 hours later. Misoprostol has a high affinity to the uterus and causes 
contractions and expulsion of the pregnancy. With misoprostol alone high and 
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repeated doses are required which can cause side effects such as nausea and 
other gastrointestinal symptoms. 
Mifepristone was developed in France in the 80s and was shown to cause 
cervical ripening and contractility of the uterus which ended with a successful 
abortion in 60-80 per cent of all cases. It was a Swedish research team who 
discovered that apart from the effect of mifepristone itself on the uterus and 
cervix it also increases the sensitivity to misoprostol and hence shortens the time 
to expulsion and makes it possible to lower the doses of misoprostol.[36] The 
combined treatment with mifepristone and misoprostol is recommended by 
WHO as the first line of treatment, but in areas where mifepristone is prohibited 
or not available the WHO has given recommendation on how misoprostol can 
be used alone.[37] 
The proportion of medical abortions is increasing and has reach very high levels 
in the Nordic countries. In 2015 medical abortions were the method of choice in 
96% of the cases in Finland, 90% in Sweden, 70% in Denmark and 87% in 
Norway. [24] The increase has been more modest in other European countries 
with a prevalence of 58% in France in 2012 and 20% in Germany in 2013.[38] 
 
Surgical abortion 
Surgical abortion can be performed either in local or under general anesthesia 
while the uterine cavity is being emptied. Dilatation and Evacuation (D&E) or 
curettage was the predominant method until the vacuum exeres (VA) was 
discovered already in the beginning of the 20th century. The method was refined 
during the 1960s and 70s when a plastic cannula was introduced and reduced the 
risks of the procedure. The method is considered very safe and is the surgical 
method of choice up to gestational week 14.[39] In the Nordic countries this is 
practically the only surgical method available since abortions in later pregnancy 
weeks are medical. In other parts of the world D&E is used in later pregnancy 
weeks.[31] 
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Post-abortion contraception 
In Europe and globally a significant proportion of women having an abortion 
have had one or more previous abortions. In Europe a variation between 21 and 
60% has been reported. In the Nordic countries the prevalence is around 
40%.[40-44] LARC has been shown to be highly effective in preventing 
unintended pregnancy and repeat abortions.[22 45-48] Studies show that most 
women  (83%) ovulate in the first cycle after a medical abortion.[49]  Other 
studies have shown that 15% of  women resume sexual intercourse within one 
week of a medical abortion[50] and 51% within two weeks.[51] Immediate start 
of any contraceptive is therefore desirable and since LARC has been shown to 
prevent repeat abortions to a larger extent than other methods LARC is 
preferable. However, the start of any method is better than no method at all in 
preventing a repeat abortion.[45] 
 
CHC, POP and progestogen-injections can be started the same day as 
misoprostol is given or a surgical abortion is performed.[13] LARC can be 
inserted immediately after a surgical abortion, with well documented 
effectiveness, compliance and safety.[52] After a medical abortion, the practice 
has been to provide LARC at a follow up visit several weeks after treatment. 
Since many women prefer performing a home-follow-up with a pregnancy test 
there is no need for a follow up visit at the health care centre. Also, many 
women who have been scheduled for follow-ups do not turn up.[53] This applies 
in particular to settings where women have to travel long distances for abortion 
care or where services are poor or expensive. Unfortunately many women then 
miss the opportunity to receive a LARC method. Therefore it would be an 
advantage if LARC could also be started immediately after medical abortions. 
Smaller studies have been performed where IUDs have been fitted within a 
week after the abortion without any adverse effects compared to the standard 
insertion weeks later.[50 54 55] Concerning implants the WHO advises 
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immediate implant insertion[13] but this practice has not been widely 
implemented due to the theoretical concerns about interaction between the 
progestogen-inhibitor mifepristone and the progestogen-containing implant 
which could affect the efficacy of the medical abortion negatively. Three pilot 
studies have reported slightly diverging results concerning success rates of 
abortion when an etonogestrel-containing implant was inserted at the time of 
treatment with mifepristone.[56-58] There is also one randomised controlled 
trial that investigated the efficacy rates of medical abortion when an implant was 
either inserted in close connection to the treatment with mifepristone or at a 
standard follow up visit, but the study misses information on how soon after the 
intake of mifepristone the implant was inserted.[59] 
 
Socioeconomic status (SES) 
SES has been shown to influence contraceptive use and rates of unintended 
pregnancies. In high-income countries, such as Canada, France, the United 
Kingdom and the United States several studies have shown that low SES is a 
risk factor for low contraceptive use, no contraception at first intercourse and a 
high rate of unintended pregnancies and abortions. [60-64] In studies in the 
Nordic countries SES has been identified as an influencing factor, but mainly in 
specific groups, such as women having a second or more induced abortion or 
immigrant women, rather than the general population.[65-67] 
Also in low and middle income countries (LMIC) low SES is associated with 
less use of contraceptives[68] but in contrast to high income countries, high 
instead of low SES is associated with a high rate of abortions. This could be 
explained by the fact that women with high SES in LMIC have a greater 
knowledge about abortion facilities than women with low SES and hence easier 
to compensate for an unmet need for contraception, which is more often the case 
in LMIC than in countries with high income.[69] 
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Several studies have focused exclusively on the impact of SES on adolescent 
pregnancy and motherhood. Socioeconomic deprivation is considered to be both 
an effect of and a risk factor for teenage births.[70-73] 
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Aims 
The overall aim of this thesis was to describe and explore the relationship 
between contraceptive use, abortion and birth rates among women in Sweden 
and the other Nordic countries.  
The specific aims were: 
• To describe and compare contraceptive availability and use in the Nordic 
countries and compare usage by age in the three countries, Denmark, 
Norway and Sweden. A secondary aim was to assess prescribing patterns 
in relation to the recommendations from the European Medicines Agency 
(Paper I) 
• To describe and compare contraceptive use, fertility, birth and abortion 
rates in different age groups in the Nordic countries (Paper II) 
• To describe and compare hormonal contraceptive use, birth and abortion 
rates among teenagers in the Nordic countries (Paper III) 
• To describe contraceptive use and pregnancies in four generations of 19-
year old women. A secondary aim was to relate contraceptive use and 
pregnancies to SES (Paper IV) 
• To compare the effect of immediate versus delayed insertion of an 
etonogestrel releasing contraceptive implant on complete abortion rates of 
a medical abortion. Secondary aims were to compare complication rates, 
insertion rates, acceptability of the timing of insertion and pregnancy rate 
within 6 months after the abortion. (Paper V)  
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Methods 
Three different types of research methodology are used in this thesis. Three of 
the studies are longitudinal and cross-sectional register-based studies, one is a 
cross-sectional questionnaire-based study and the fifth study is a randomised 
controlled equivalence trial. 
 
Observational studies 
Conditions in the Nordic countries are favourable for epidemiological studies. 
There are population registers with a personal identification number system 
containing information on the total population of each country providing the 
ability to obtain random samples of the total population. In addition to the 
population registers there are national databases on a large number of health 
related topics such as medical prescriptions, births and abortions. 
 
Paper I, II and III 
Data for Paper I, II and III was collected from national databases in the five 
Nordic countries; Denmark, Finland, Iceland, Norway and Sweden. The 
following databases were utilised: National Health Registries[74], the Tigrab 
Database[75]and the Danish National Registry of Medicinal Product Statistics, 
[76] in Denmark, the National Institute for Health and Welfare[24] and the 
Finnish Medicines Agency[77] in Finland, the Directorate of Health[78] and the 
Icelandic Medicines Agency[79] in Iceland, the Norwegian Institute of Public 
Health[80] and the Norwegian Prescription Database[81] in Norway and the 
National Board of Health and Welfare in Sweden[82]. Birth and abortion rates 
were according to international praxis defined as the number of births or 
abortions per 1000 women aged 15-44 during one year.[23]  
To estimate contraceptive use data on redeemed prescriptions of hormonal 
contraceptives was retrieved from the national databases and sales figures for 
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the Nova-T intrauterine device (IUD) from the main manufacturer (Bayer AG, 
Berlin, Germany). The data was presented as Defined Daily Doses (DDD). In 
these studies contraceptive use is defined as DDD/100 women and day, i.e. 
percentage of women using contraceptives.  In accordance with international 
practice women 15-49 years of age were included. [83].  
Use of methods such as fertility awareness methods, condoms and diaphragms 
was not estimated since they are not registered. Women who were infertile, not 
heterosexually active, pregnant or had the wish to get pregnant were included 
in the study population since all variables were collected on a group level from 
anonymous data concerning women of reproductive age (15-49). 
Demographic data was collected from Facts about the Nordic Region[84] and 
information about policies, guidelines and legislation concerning 
contraceptives and abortions was collected from each Nordic country by 
members of the research group. 
In paper III total fertility rates (TFR) for all Nordic countries were collected 
from Eurostat[85]. TFR was defined as the average number of live births a 
woman would ever deliver if she were to experience the fertility rate of a given 
period and survive through her reproductive period of life. 
 
Paper IV 
Paper IV is based on data retrieved from postal questionnaires sent out to a 
random sample of 19-year-old women resident in Gothenburg. In 1981 a 
prospective longitudinal population study of women living in the city of 
Gothenburg was initiated[86]. The women were born 1962 and were 19 years of 
age. This age was chosen in order to be able to collect the information from the 
women themselves without parental consent. A random sample of every fourth 
woman was obtained (n = 656) from the population register.  
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In 1991, a new group of 19 year-old women (born in 1972), also residing in 
Gothenburg, was invited to participate in the study. A one in three sample (n = 
780) was obtained from the population register.  
A similar postal questionnaire was sent out ten years later in 2001 to a third 
cohort of 19-year old women (born 1982). A one in three sample (n = 666) was 
obtained at random from the population register.  
In 2011 the last cohort was recruited among women born 1992. Due to declining 
response rates all 19-year-old women in the Gothenburg region were invited to 
participate. Apart from postal questionnaires also electronic reminders and 
questionnaires translated into English were used in the assessment in 2011. 
The questionnaire consisted of approximately 40 questions about contraception, 
pregnancies, reproductive history and factors such as height, weight and 
smoking. The questionnaire has undergone only minor changes during the 
course of this study as it was considered of importance that the same questions 
were asked on each assessment. The only changes that were made consisted of 
new questions about contraceptive methods that were not available when the 
study started in 1981, e.g. implants and the levonorgestrel-releasing intrauterine 
system.  
The Swedish population register contains information regarding civil status, 
nationality, home address, income and level of education linked to the 
individual's personal identification number. Each district in the city of 
Gothenburg has been classified according to a three-point socio-economic index 
(low, medium and high SES) based on the mean level of education, income and 
profession/social group for all the inhabitants in each district.[87 88] Using this 
index, it was possible to group the study participants into three levels of SES. 
 
Randomised controlled study -Paper V 
Paper V was performed as a randomised controlled equivalence trial. An 
equivalence design, instead of superior design, was chosen since the method we 
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aimed to study had advantages for women, such as fewer visits to the clinic, 
when compared to the standard method. 
Women with pregnancies below 64 days gestation and opting for the 
etonogestrel releasing subdermal implant (Nexplanon®) as post abortion 
contraception, were asked to participate. Participants were recruited at outpatient 
family planning clinics from five Swedish sites and one Scottish site. 
Participants were randomised to either immediate insertion of the implant one 
hour after swallowing mifepristone (Mifegyne®) or to insertion at the follow up 
visit 2-4 weeks later (standard method).  The study was unblinded for ethical 
and practical reasons. 
All women received mifepristone 200 mg in the clinic and 24-48 later vaginal 
misoprostol 800 mcg hours was administered. Follow up was either in the clinic 
or via telephone using a self-performed low sensitivity urinary hCG-test two to 
four weeks later[53 89]. At the follow up women completed a questionnaire 
with questions regarding: duration and quantity of bleeding; the worst pain they 
had experienced during the abortion on a visual analogue scale (1-10); if they 
had had unscheduled visits to the abortion service; if they had received any extra 
treatment for a complication related to the abortion; and if they would prefer 
immediate or delayed insertion if they were ever to have a medical abortion 
again. All centres in the study had access to patient records for the entire region 
in which the abortion took place.  
The primary aim was to determine if immediate insertion is equivalent to 
delayed insertion (standard treatment) for a successful completion of the 
abortion without the need for vacuum aspiration. Assuming 97% success in both 
groups, and a two sided margin of equivalence (-5% - 5%) 252 patients per 
group would be required to establish equivalence with an alpha of 0.05 and a 
power of 90%. The primary outcome was assessed at follow up at two to four 
weeks, and/or by patient records.  
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Secondary outcomes were serious adverse events and adverse events of special 
interest, rates of insertion of the implant and preferred allocated time of 
insertion. Furthermore satisfaction with the implant, continued implant use and 
pregnancies and repeat abortions where reported by the patients at telephone 
follow up three and six months after the abortion. 
 
Statistical analysis 
 
Paper IV 
Fisher’s exact test and ANOVA with Tukey’s Studentized Range (HSD) test for 
post hoc comparisons were used in the analysis of possible differences in basic 
characteristics, contraceptive use and pregnancy outcome between the four 
cohorts (SAS 9.1; SAS Institute Inc., Cary, NC, USA). 
 
Paper V 
The primary outcome was analysed with a generalised estimating equation 
model using a binomial distribution and an identity link and presented as a risk 
difference with a 95% confidence interval. The intention to treat (ITT) 
population was defined as all women randomised except women who withdrew 
consent before abortion or insertion of the contraceptive implant, or did not 
receive medical abortion (Figure 7). The per protocol (PP) population was 
defined as all women in the ITT analysis except those who changed their mind 
about method of contraception before insertion of the implant or had implant 
insertion at the wrong delayed timing. The primary analysis was performed on 
the PP population corroborated by the ITT population. This is in accordance 
with the CONSORT statement since the usually smaller differences in the ITT 
analysis makes it easier to establish equivalency/noninferiority and is considered 
anticonservative as opposed to when it is used in superior studies. In addition a 
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sensitivity analysis was performed excluding all women in the PP population 
who did not come for follow up. All other analyses were presented for the ITT 
population. Fisher´s exact test was used to evaluate the differences between the 
groups regarding categorical data. Continuous variables are presented as 
medians and range and compared between groups using Mann-Whitney U-test. 
Differences were considered statistically significant if the two sided p-value was 
less than 0.05.  
 
Ethical approval 
 
Paper I-III 
In Norway, the board of the Norwegian Prescription Database reviewed the 
study protocol and gave permission for use of the data. Studies using 
anonymous data from nationwide registers are by Norwegian legislation 
exempted from the need of institutional regulatory board approvals and written 
informed consent from the patients. In Denmark, permissions were achieved 
from Datatilsynet (journal no 2010-41-4778). In Finland, Iceland and Sweden 
no ethical approval was required as these anonymous data are publicly available 
from the national bodies of these countries. Patients were not directly involved 
in the study since only aggregated data on group-level was used. 
Paper IV 
 
The study was approved by the Ethics Committee in Gothenburg, Sweden (e.g. 
1981: 023; 2006: 330; 2011: 778). The National Data Inspection Board 
approved the study design and informed consent was obtained from each 
participant. 
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Paper V 
The institutional review board of Karolinska Institutet, Stockholm, Sweden, 
granted ethical approval for all Swedish sites (permit no 2013/907-31/4). The 
ethical committee approval number for the Edinburgh site was IRAS 141042 ref 
14/SS/011. 
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Methodological considerations 
 
Paper I-III 
The fact that abortions and births rates traditionally are described as the 
number/1000 women aged 15-44 years while contraceptive use is described as 
the percentage of women aged 15-49 years using contraception, constituted a 
challenge when we merged the data into one set. Other options, .e.g to present 
both births, abortions and contraceptive use either as number/1000 women or as 
the percentage of women, were discussed in the research group, but in order to 
be able to compare our results with other studies we chose the standard way of 
presenting the data.  
Many studies, including European surveys, describe contraceptive use 
prevalence as percentage of all women 15-49 years of age. However, as 
discussed in the Introduction, studies on a global level often describe 
contraceptive use only among women who are married or in-union. This has to 
be taken into consideration when comparing the results in this thesis with those 
studies[3]. 
Since the study population includes all women in a certain age group and not 
only a sample of observations all measures were highly significant. To illustrate 
the accuracy of this statement the chi square p-value for two randomly chosen 
differentials in the data set were calculated (Table 2). 
Table 2. 
Data from Paper II,  
year 2013 
Denmark Finland Norway p-value 
Total hormonal 
contraceptive  
user rate 
39,9%	 39,7%	  0.0015	
CHC user rate 26,3%	  17,9%	 <0.00001	
 
  40 
Even for such a small difference as 0,2% the p-value was 0.0015 and it was not 
detectable for the comparison of CHC user rates in Denmark and Norway.  
 
Paper IV 
In order to validate the reliability of the questionnaire it was tested by letting 30 
women answer the questionnaire twice with a 3-week-interval. The agreement 
of the answers to five specific questions was checked (agreement ranged 
between 90-100%). Furthermore ten questions were selected and understanding 
of the questions was checked in a group of 10 women. The level of 
understanding ranged from 89-100%, which was considered satisfactory.  
 
Paper V 
Altogether 12 women were excluded from the study after randomisation but 
before the treatment had actually started. If the randomisation had been done 
even closer to the start of the abortion this loss of research persons might have 
been reduced. Since 8 out of 12 withdrew their consent one has to consider if the 
information about the study had not been sufficient before the randomisation 
procedure. 
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Results 
Paper I 
In this paper contraceptive use in the Nordic countries from 2010 to 2013 was 
explored with an emphasis on LARC, adherence to recommendations from 
European Medicines Agency (EMA) and emergency contraception (EC). The 
study population consisted of 5 814 064 women aged 15-49 years in 2013.	
 
In all countries there was a slight increase in hormonal contraceptive use from 
2010 to 2013. Finland and Denmark had the highest rate of overall hormonal 
contraceptive   use,  increasing   from  38  to 40%;  Iceland  had  the  lowest  use  
(30–31%). 
 
LARC 
The use of LARC increased successively over time in all countries except in 
Norway. In 2013 Sweden had the highest rate of LARC with 20% followed by 
Finland 18%, Denmark 16%, Norway 11% and Iceland 10%. The percentage 
use of LNG-IUS and Cu-IUD was 11%/3% in Denmark, 8%/2% in Iceland, 
8%/1% in Norway, 15%/1% in Finland and 11%/7% in Sweden. 
 
Use of COC recommended as first line treatment 
Comparisons were made between the use of COC recommended as first line 
treatment by the EMA versus other forms of CHC products. In Denmark the 
proportion of EMA-recommended products increased markedly from 13% to 
50% between 2010 and 2013. Finland remained almost exclusively on non-
recommended products throughout the study period, while in Iceland and  
Norway the proportions of recommended products increased to some extent. 
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Sweden started off at a high level of recommended products with a slight 
decrease during the study period. 
 
Emergency contraceptive pill  
Norway had the highest sales figures for emergency contraceptive pills with 
12.6 sold packages/100 women in 2013 and Denmark the lowest with 8.2 sold 
packages/100 women. All countries had a slight decrease in the use of 
emergency pills during the period 2010 - 2013.   
 
Paper II 
In this paper contraceptive user rates and fertility, birth and abortion rates in the 
Nordic countries were explored. When possible data were also stratified 
according to age groups with a 5-year-interval. The study population consisted 
of 5 814 064 women aged 15-49 years in 2013. 
	
Fertility, birth and abortion rates among women of reproductive age 
FR remained stable around 1.8 in all countries except for Iceland where the rate 
declined from 2.7 to around 1.9. In 2013 the fertility rate was 1.7 in Denmark, 
1.8 in Finland and Norway and 1.9 in Sweden and Iceland. 
Birth rates displayed similar patterns as the overall FR in all countries. 
Abortion rates declined in Denmark and Finland, increased in Iceland and 
remained stable in Norway and Sweden. The changes in abortion rates took 
place mainly between 1975 and 1995 whereas from 1997 and onwards a 
relatively stable pattern was seen in all countries.  
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Contraceptive use among women of reproductive age 
The overall use of hormonal contraceptives and Cu-IUD among women aged 
15-49 years during 2008-2013 was higher in Denmark (39-44%), Sweden (40-
42%) and Finland (40-41%) compared to Norway (33-34%) and Iceland (31-
33%). The levels of hormonal contraceptive use in each country were fairly 
stable during 2008-2013, with the exception of Denmark where a small increase 
was noted mainly due to an increasing use of the LNG-IUS. In 2013, the 
estimated use of Cu-IUD´s and POP was highest in Sweden (7% for each 
methods) whereas Finland had the highest use of the LNG-IUS (15%). 
 
Hormonal contraceptive use, birth and abortion rates in different 
age groups 
Hormonal contraceptive use, birth and abortion rates for Denmark, Norway and 
Sweden during the period 2008-2013 were also stratified according to age. The 
age group 15-19 years is described in the section on Paper III.   
In summary CHC was the most common method in the age groups ranging from 
15-29 years of age for all three countries. In the age groups 34-44 CHC 
decreased gradually whereas the use of LNG-IUS increased to become the 
dominant contraceptive method. This changing scenario was seen in older age 
groups in Denmark than in Norway and Sweden. 
In all three countries, births reached a peak among 30-34 year old women and 
abortion rates were highest among women of 20-24 years of age. Sweden had 
the highest abortion rates and lowest rate of contraceptive use in the age group 
20-24 years. 
 
Paper III 
In this paper trends in contraceptive use, abortion and birth rates among all 
teenagers in the Nordic countries were explored. For Denmark, Norway and 
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Sweden the study population was also stratified into the subgroups of 13-14, 15-
17 and 18-19 years old women. The study population consisted of all 749 709 
15-19 years old women in all Nordic countries and all 815 044 13-19 years old 
women in Denmark, Norway and Sweden respectively in 2015. 
 
Overall birth and abortion rates among teenagers 15-19 years, 1975-
2015 
There has been a steady decline in teenage pregnancies during the study period 
attributed to a decline in both abortions and births (Figure 6).  Abortion rates 
varied to some extent until 1999 but have thereafter declined continuously in all 
the Nordic countries and reached their lowest levels ever in 2015. 
 
 
Figure	6.	Pregnancies,	including	births	and	abortions,	among	teenagers	1975-
2015	in	the	Nordic	countries.		
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Age-stratified use of hormonal contraceptives, births and abortions 
in Denmark, Norway and Sweden, 2008-2015 
Both rates of contraceptive use, births and abortions were very low among 13-14 
years old women. Denmark had a higher use of hormonal contraceptives among 
15-17-year-olds (from 40 to 34%) compared to Norway (from 25 to 27%) and 
Sweden (from 29 to 30%). Among 18-19 year-old women user rates went from 
63 to 61% in Denmark, 56 to 61% in Norway and 54 to 56% in Sweden.  A 
more marked decrease in birth rates was seen among 18-19-year-old in Norway 
(from 20 to 10 per 1000 teenagers) compared to the other two countries where 
Norway started off on a higher level in 2008 (Fig. 3c).  
 CHC were the most popular contraceptive methods in all age groups, especially 
among the Danish teenagers. There was an increase in LARC among 15-17-
year-olds, but this was more marked among the 18-19-year-olds with levels 
increasing from 2 to 6% in Denmark, 2 to 9% in Norway and 7 to 17% in 
Sweden. This was mainly due to increasing levels of LNG-IUS in Denmark and 
Sweden and of implants in Norway.  
 
Paper IV 
In this paper a number of reproductive health issues and their relationship to 
SES in four generations of young Swedish women was investigated.  
 
Current contraceptive use was higher in 2001 (78%) (p < 0.01) and 2011 (69%) 
(p < 0.05) compared with 1981 (60%) and 1991 (62%). CHC was the most 
common form of contraception in all cohorts (p < 0.0001) but there was a 
modest increase of LARC in the later cohorts. 
 
The proportion of teenage mothers decreased from 4.4% (1981) to 1.6% (2011) 
(p < 0.01). BMI was significantly higher in the last cohort compared to the two 
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first cohorts (p < 0.001). The proportion of smokers decreased successively 
between the four cohorts from 41% in 1981 to 19% in 2011 (p < 0.001). 
 
The percentage of young women who had ever been pregnant at ≤19 years of 
age was lower in the assessment from 2001 (7.4%) (p < 0.05) than in 1991 
(12.9%) and 2011 (12.2%) which corresponds to the pregnancy rate described in 
Paper III. In 2001 there had been a decline in pregnancies during the five years 
before the questionnaire was sent out and vice versa in 1991 and 2011 (Figure 
1b, Paper III).  
 
Association between SES and contraception, pregnancy, smoking 
and BMI 
There was no significant difference in the prevalence of current or ever use of 
contraception according to SES area in 1981, 1991 and 2001, but in 2011 there 
was a lower prevalence of contraceptive use in low SES areas compared to both 
of the other SES groups. More women had been pregnant in the low SES areas 
than in the higher SES areas (p < 0.05) in 1981, 1991 and 2011.  
 
There were more smokers in low (p < 0.05) SES areas compared to high SES 
areas in 1981 and 1991, but no correlation between SES and smoking in 2001 
and 2011. BMI was higher in the low SES groups (p < 0.05) in 2001 and 2011. 
	
Paper V 
This study investigated if immediate insertion (1 hour after the intake of 
mifepristone) of a subdermal contraceptive implant affected the efficacy of 
medical abortion compared to the standard treatment with delayed insertion at 
the follow up visit, in a randomised controlled equivalence trial. 
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The study population was enrolled between October 2013 and October 2015 and 
in the ITT population 261 women were scheduled for delayed insertion 
(standard treatment) and 277 to immediate insertion. The flow of patients is 
described in Figure 7.  
 
Figure 7. Trial flow-chart. Source Paper 5. 
 
The main outcome was successful completion of the abortion without the need 
of a surgical intervention. In the PP analysis 16/274 (5.8%) of women in the 
immediate insertion group and 10/249 (4%) in the delayed insertion group had a 
surgical intervention resulting in a risk difference of 1.8% (95% CI −0.4% to 
4.1%). Since this was within the pre-specified margin of ±5% equivalence 
between the two groups could be established. The results were similar for the 
ITT population with a risk difference of 1.3% (95% CI −0.9% to 4.1%). 
Insertion rate and acceptability of time of insertion was statistically higher in the 
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group of immediate insertion and there were fewer pregnancies in the group of 
immediate insertion than delayed. Table 3. 
Table 3. Primary and secondary outcomes. 
 Immediate insertion Delayed insertion  
Surgical 
intervention 16/274 (5,8%) 10/249 (4%) 
Risk difference 
1,8%* 
Insertion rate 274/277 (99,2%) 187/261 (71,6%) P<0.001 
Pregnancy 
within 
6 months 
2/274 (0,7%) 10/261 (3,8%) P=0.018 
Acceptability 
of time of 
insertion 
180/277 (64,9%) 51/261 (19,5%) P<0.001 
*Risk difference 1,8% (95% CI -0,4-4%) Equivalence within +5% established 
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Discussion 
 
Fertility rate 
While a large part of the world outside Europe is still in the middle of the 
fertility transition with a strong wish among its inhabitants to lower their TFR, 
Europe’s concern is instead a declining or stable low TFR well below 
replacement level which is illustrated in Figure 8.[85] All the Nordic countries 
have kept a higher TFR than the rest of Europe since 1990 and onwards. 
 
Figure 8. Total fertility rate in the Nordic countries and Europe. Source: Paper 
II and Eurostat (the broken line). 
 
Studies show that governmental support for combining family with a working 
career is the key to keeping a high birth rate and TFR.[90 91] The means for 
this might differ from country to country. In the Nordic countries parental leave 
for both women and men and accessible and affordable child-care is offered. 
Also in France there is a strong support for combining work and family life and 
France has a TFR similar to the Nordic countries. The Nordic countries and 
France are both good examples of that it is possible to combine high birth rates 
with good access to family planning methods including safe abortion on 
women’s request.[90 91] 
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Increasing use of LARC 
There is robust scientific evidence of the high efficacy of LARC methods [18 
46]. During the last 10-15 years the promotion of LARC as the most effective 
form of contraception has increased. Still only a very small increase of LARC 
was noticed between 2008 and 2013 in Paper I and II. The positive trend 
towards increasing use of LARC is much more obvious among the oldest 
teenagers in Paper III, which also covers the years 2014-2015. The finding is 
supported by Paper IV where an increase of LARC among teenagers in a longer 
perspective is seen. There was a shift towards recommending LARC already in 
the Swedish guidelines for contraception in 2005 which was updated in 2014. 
Norway has done similar recent updates. The evidence for LARC being suitable 
also for teenagers is still growing. In a review, including 12 studies and 4886 
women, on the use of LARC among adolescents an overall continuation rate of 
84% after 12 months of use was found. The majority of the adolescents in this 
review were using an IUD.[92] Another review focusing specifically on LNG-
IUS confirmed the high continuation rate, but also examined the effect on 
treatment of dysmenorrhea, endometriosis and menorrhagia. A high 
acceptability and reduction in symptoms was found.[93] The continuation rates 
described in these studies are very high compared to continuation rates of non-
LARC methods such as COC, the patch, the ring and DMPA-injections. In a 
sub-analysis of the CHOICE project 81% of women aged 14-19 years continued 
with LARC but only 44% with non-LARC. There was also a lower continuation 
rates of non-LARC methods when compared with older women in the same 
study. [94] Even lower 1-year-continuation- rates for non-LARC were observed 
in a study by Raine et al where only 32,7% continued with COC.[95] 
The results from Paper V where it was shown that one of the LARC methods, an 
implant, can be offered at the same day as a woman is having an abortion and 
therefore only needs one visit to the abortion clinic is an important contribution 
to the spreading of this highly effective LARC.  
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The relationship between contraception and abortion 
prevalence  
 
In Paper II and III there was no clear correlation between high overall 
contraceptive user rates and low abortion rates and vice versa when the Nordic 
countries were compared. For instance Iceland with the lowest contraception 
prevalence also had the second lowest abortion rate while Sweden with the 
second highest contraception prevalence had the highest abortion rate. Among 
the teenagers in Paper III births and abortions declined in all countries to its 
lowest levels ever at the same time as LARC increased, but still the correlation 
between highest contraceptive use and lowest abortion rate was absent. A 
number of possible reasons for this have been discussed in Paper I and II:  
 
• a lower contraceptive user rate in the highly fertile and sexually active 
age group of 20-24-year old women in Sweden compared to the same age 
groups in Denmark and Norway. This is the age group with the highest 
abortion rate. 
• we were not able to estimate the proportion of women using no method at 
all or methods such as condoms, diaphragms, fertility awareness methods 
or coitus interruptus.  The proportion of non-users and users of the 
mentioned methods, which are highly user-dependent, might differ 
between the countries and affect unintended pregnancy rates. 
• the proportions of different hormonal methods vary between the 
countries. Sweden had  a higher user rate of POP than the others and the 
continuation rate for POP is lower than for other oral methods.[96] 
 
Other approaches might also be considered. In 2010-2014 the global abortion 
rate was 35/1000 women 15-44 years of age and in the developed world 
27/1000. In a global context all the Nordic countries have low abortion rates, 
including Sweden. This in turn means it is not as easy to detect a certain factor 
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to further lower these rates, compared to countries with huge unmet need for 
contraception where any increase in any contraception method probably will 
have an effect. As discussed in the Introduction a country may have increasing 
contraceptive prevalence and increasing abortion levels at the same time since 
both might be needed for a limited period of time to reach the fertility rate and 
number of children one wishes for. With time abortion rates usually stop 
increasing when the contraception prevalence is high enough to cover the main 
need for contraception and the fertility rate is stable. The abortions that still 
occur then are mainly due to contraceptive failure or non-use.  Other parameters 
might change though which increase the unmet need for contraception again. As 
for many other countries the average age for having a first child has increased 
from 24 in 1970 to 29 in 2010 in Sweden and since the years between 24 and 29 
is a period of high fertility the time with a need for highly effective 
contraceptives is extended. This has been illustrated in the French paper 
Effectiveness of family planning policies: The abortion paradox. Also in France 
the average age for having a first child has increased during the last 40 years 
with a concomitant increasing need for effective contraceptives.  
As shown in Figure 9 the authors reported an increasing contraceptive 
prevalence among women 18-29 years of age but an almost unchanged abortion 
rate. An extended need for effective contraceptives has been met and an 
increasing number of unwanted pregnancies has been avoided but very little has 
happened to the abortion rate.[97] This might be the case also in Sweden and 
Norway where the abortion rates has remain stable since 1975. There is support 
for an increasing contraception prevalence from 1981 to 2011 in Sweden in 
Paper IV. 
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Figure 9. Trends in unwanted pregnancies, probability of ending them,  
abortion rates and very effective contraception rate for women 18–29.Left axis: 
rate per woman. Right axis: Percentage. Source: Effectiveness of family 
planning policies: the abortion paradox. Bajos, N et al. PLoS one, 2014, 9(3) 
 
Adherence to EMA recommendations	
From 2009 epidemiological studies have shown a differential risk of venous 
thrombosis according to type of progestogen in COC [98] and the EMA has 
updated its recommendations on first line COC to be those containing 
levonorgestrel, norgestimate or norethisterone, which have the lowest risk of 
venous thrombosis.[99] During the study period 2010-2013 in Paper I the 
adherence to this recommendation varied substantially between the Nordic 
countries with the highest level in Denmark (50% in 2013) and the lowest in 
Finland (1% in 2013). This might imply that the time has come for mutual 
guidelines on contraception for all Nordic countries. 
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Discontinuation due to mental effects  
In Paper IV mental side effects, such as depression and reduced libido, as 
reasons for discontinuation of CHC use increased substantially over time across 
the four cohorts from 15 to 55% (p < 0.001). This is in accordance with other 
epidemiological studies, but other explanations than the use of CHC itself has 
been sought for, such as important life events or depression already before the 
start of the CHC. In a review article it was found that 15% experienced a 
decreasing libido during the use of CHC [100], but the study designs varied. 
Two Swedish randomised placebo-controlled trials have recently been 
conducted in order to evaluate side effects of COC. In one study COC use was 
associated with small but significant mood side effects in the intermenstrual 
phase. The findings were driven by a subgroup of women who clearly suffered 
from COC-induced side effects.[101] In the other study, where effects on libido 
were investigated, no significant reduction in overall sexual function was found 
in the COC group compared to the control group, but there was a significant 
impairment in three out of seven sub-domains: sexual desire, arousal and 
pleasure.[102] Although small, these findings should be taken into consideration 
in the contraceptive counselling. 
 
The impact of socioeconomic status (SES) 
The association of low SES and lower contraceptive use and higher teenage 
pregnancy rate in Paper IV is consistent with the findings in other studies from 
high income countries.[60-64] It is also in accordance with the result of studies 
from other parts of the health care sector. For instance, Hakeberg and Wide 
Boman have reported about poorer oral and general health in low SES areas in a 
study also conducted in the Gothenburg area.[103] Bergstrom et al have shown 
that the outcome after an acute myocardial infarction is worse for residents from 
low SES areas in Sweden.[104] 
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What is notable in the results in Paper IV though, is that there was no detectable 
difference in contraceptive use between the three SES groups in the three early 
cohorts of women, but in the assessment from 2011 a difference was shown. 
This implies a widening inequality in more recent years. It also suggests that 
there is a greater need for information and sexual education in low SES areas in 
order to reverse this trend. 
Also a proportionally higher BMI was recorded in low SES compared to high 
SES areas in the later cohorts from 2001 and 2011 compared to the analyses 
from 1981 and 1991. This might have implication on the contraceptive 
prevalence since an increasing BMI limits contraceptive choices. 
 
Response rate 
Response rates in epidemiological studies have declined steadily for many years 
[105]. In a review on response rate of surveys performed during 1970-2003 the 
steepest decline was seen after 1990. The overall decline varied between ≈0,5-
2%/year and was dependent on the study design. Cohort and cross-sectional 
studies, which applies best to Paper IV, had a decline of 0,54%/year.	It 
corresponds well with the response rates in Paper IV where the response rate 
was 91% in 1981, 82% in 1991, 77% in 2001 and 53% in the last cohort of 
women included in 2011. Due to the knowledge of declining response rates the 
sampled population in 2011 was increased to 100% of the total population of 19-
year-old women.  It has been suggested that web-based surveys might increase 
the response rate but the results from earlier studies have been divergent. In 
more recent studies web-based surveys seems to have the same response rates as 
postal surveys though. [106 107] In a Cochrane review from 2009 a number of 
factors were found to increase response rates, such as pre-notification, follow-up 
contact, shorter questionnaires, providing a second copy of the questionnaire at 
follow up, mentioning an obligation to respond, university sponsorship, 
incentives and an assurance of confidentiality. The odds of response were 
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reduced when the questionnaire included questions of a sensitive nature. [108] 
For future studies or follow-up of the present cohorts in Paper IV these factors 
along with a web-based survey option should be considered. 
 
Strengths and limitations 
The strength of Paper I-III was the use of national register data, where all 
women of reproductive age in the Nordic countries are included.  All the 
registries are considered reliable.  
Data on redeemed prescriptions have been extracted from the databases. When 
assessing contraceptive use, pharmacy claims have been shown to be more 
reliable than self-reported use.[109]  
Online purchases of pharmaceutical drugs without a registered prescription are 
not included in the study. Since prescribed hormonal contraceptives are 
available and affordable to most women of reproductive age in the Nordic 
countries, the proportion of online purchases without a prescription is not 
considered to be significant.   
A limitation in Paper I-III was the lack of age specific data on contraceptive use 
from Finland and Iceland. This would have been of special interest since Finland 
has the lowest abortion rate. Another limitation in Paper I-III was the lack of age 
specific data on Cu-IUDs and the lack of data on all other non-hormonal 
methods. 
The main strength of Paper IV was the design that allowed a comparison of 
contraception, pregnancies and other health factors in random samples of 
women of the same age from the same urban area during a period of 30 years. 
Another strength was the possibility to connect this information to the SES of 
the area of residence and hence assess the possible influence of socioeconomic 
factors.  
  57 
A limitation in Paper IV was that the response rate to the questionnaire 
successively decreased during the course of this 30- year study. The lower 
response rates in the most recent cohorts compared to the earlier cohorts is in 
agreement with the successive reduction in response rates to questionnaires 
reported in the literature. 
The strength of Paper V was the randomised equivalence trial design and the 
fact that it was a multi-center study, which ensures that the results are 
independent of the study centre. The limitation was the loss to follow-up, but the 
proportion of women who did not complete follow-up did not differ between 
groups and the results of the sensitivity analysis did not differ from the ITT or 
PP analysis. 
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Conclusions 
 
• The user rates of hormonal contraceptives and Cu-IUD among all women 
of reproductive age in the Nordic countries varied between 31% and 44% 
in 2008-2013. The highest use was in Denmark and the lowest in Iceland. 
CHC followed by the LNG-IUS were the most common methods. A small 
increase of LARC was detectable during the study period (Paper I and II). 
• The overall abortion rates of the Nordic countries fell during the study 
period with declining rates in Denmark and Finland, increasing rate in 
Iceland and stable rates in Norway and Sweden. The changes in abortion 
rates took place mainly between 1975 and 1995 whereas from 1996 and 
onwards a relatively stable pattern was seen in all countries (Paper II). 
• In contrast to the declining average fertility and birth rates in Europe, 
rates in the Nordic countries remained stable from 1975 and onwards and 
close to the replacement level (Paper II). 
• The user rates of hormonal contraceptives among teenagers 18-19 years 
of age were rather similar in Denmark, Norway and Sweden and varied 
between 54% and 63%. CHC were the most common method, but a more 
pronounced increase of LARC, compared to the group of all women of 
reproductive age, was seen in all the countries (Paper III). 
• Teenage birth and abortion rates declined continuously since 1975 and 
reached an all-time-low in 2015 in all the Nordic countries (Paper III). 
• There was no clear correlation between higher overall hormonal 
contraception prevalence and lower abortion rate. Instead other factors 
have to be considered, such as: differences in the proportions of different 
types of hormonal contraceptives and in prevalence in specific age 
groups; the increased need for contraceptives due to delayed childbirth; 
and the lack of data concerning non-users and users of non-hormonal 
contraceptives (Paper II and III). 
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• Lower contraceptive use in low SES areas compared to middle and high 
SES areas was detected in the most recent assessment of 19 years-old 
women in the Gothenburg area. This was not seen in the earlier 
assessments and may imply a widening inequality in more recent years 
(Paper IV). 
• A contraceptive implant can be inserted on the same day as administration 
of mifepristone for early medical abortion. It has the potential to increase 
both satisfaction with the abortion procedure for women and the number 
of women who receive the most effective methods of contraception at the 
time of abortion (Paper V). 	
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Future perspectives 
During the work with this thesis the difference between the Swedish abortion 
registry and the registries in the other Nordic countries has been made apparent.  
Since all abortion patients have been anonymised already before being reported 
to the National Board of Health and Welfare in Sweden it is impossible to 
follow e.g. complication rates or connect the registry to the prescription 
database, which would make it possible to identify what contraceptive 
prescriptions women who have had an abortion have received. From the 1st of 
February 2017 abortions should be reported to the patient registry though, which 
will hopefully improve the possibility to secure the quality of the abortion care 
and also make research on abortion-related issues easier. 
While the new reporting procedures of abortions in Sweden might improve 
research nationally many of the challenges in research on abortions 
internationally will not be solved with the help from registries. On the contrary, 
after the introduction of medical abortion many abortions are now being handled 
completely by the woman herself. This takes place in countries were abortion is 
illegal and/or health care facilities do not offer abortion care. The drugs are 
purchased on the internet, in pharmacies or from private persons. Kapp et al 
have summarised the research gap concerning self-induced medical abortion, its 
methodological challenges as well as important research question about safety, 
needs of education and support and safe distribution of high quality medical 
abortion drugs.[110] Important research has already been done on home-
abortion[111] and self-test for follow up[53] in high-income and liberal settings 
which have made way for self-use in poorer or more restrictive settings. This is 
an interesting field of research. 
Not only abortions but also contraceptive user patterns might be increasingly 
challenging to follow by registries, also in the Nordic countries. Although 
contraceptives are easily accessible and affordable for many women and men, 
many find it comfortable to purchase goods on the internet and this might also 
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be the case for contraceptives in the future. Regulations might support 
registration of the purchases, but not necessarily.  Surveys, in the form of 
questionnaires or interviews, will probably be needed also in the future when 
studying contraceptive use, unintended/intended pregnancies, abortions and 
other reproductive health issues. 
The findings in Paper IV which may imply increasing inequality concerning 
contraception prevalence in low and high SES areas calls for research on how to 
reach and empower the most vulnerable women in the society. 
LARC has many advantages, the high effectiveness being the most important, 
but it has one disadvantage: it has to be inserted by a trained person. A long-
acting method that the woman could apply herself sounds like the ultimate 
method, also suitable in settings where there are no health care facilities. In fact, 
The Population Council has developed a one-year combined hormonal 
contraceptive vaginal ring, which is fitted by the woman herself, and is now 
awaiting permission from the FDA to distribute the ring.[112] Just like the self-
administered medical abortions, this is also in line with increasing self-use and 
self-monitoring instead of in-facility-care. As long as research guarantee that the 
methods are safe and efficient the development towards a well-informed self-
management of reproductive health issues should be welcomed since it 
empowers women and gives them control over their own lives.  
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